目次

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Market Definitions
1.2. Regional Scope
1.3. Estimates & Forecasts Timeline
1.4. Objectives
1.4.1. Objective 1
1.4.2. Objective 2
1.5. Research Methodology
1.6. Information Procurement
1.6.1. Purchased database
1.6.2. GVR’s internal database
1.6.3. Secondary sources
1.6.4. Primary research
1.7. Information or Data Analysis
1.7.1. Data analysis models
1.8. Marker Formulation & Validation
1.9. Market Model
1.9.1. Commodity flow analysis
1.10. List of Secondary Sources

Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Presence of strong pipeline product portfolio
3.2.1.2. Introduction of technological advancements in drug delivery
3.2.1.3. Implementation of favorable government initiatives & external funding for R&D exercises
3.2.1.4. Rising collaborations between pharmaceutical companies
3.2.2. Market Restraint Analysis
3.2.2.1. Expensive and tedious research programs
3.2.2.2. Delivery of RNAi therapeutics and off-target effects
3.3. Industry Analysis Tools
3.3.1. Porter’s Five Forces Analysis
3.3.2. PESTEL Analysis
3.3.3. COVID-19 Impact Analysis

Chapter 4. Technology Business Analysis
4.1. Antisense and RNAi Therapeutics Market: Technology Movement Analysis
4.2. RNA Interference
4.2.1. RNA Interference Market, 2018 - 2030 (USD Million)
4.3. Antisense RNA
4.3.1. Antisense RNA Market, 2018 - 2030 (USD Million)

Chapter 5. Application Business Analysis
5.1. Antisense and RNAi Therapeutics Market: Application Movement Analysis
5.2. Ocular
5.2.1. Ocular Market, 2018 - 2030 (USD Million)
5.3. Cardio metabolic & Renal Disorders
5.3.1. Cardio metabolic & Renal Disorders Market, 2018 - 2030 (USD Million)
5.4. Respiratory Disorders
5.4.1. Respiratory Disorders Market, 2018 - 2030 (USD Million)
5.5. Cancer
5.5.1. Cancer Market, 2018 - 2030 (USD Million)
5.6. Neurodegenerative Disorders
5.6.1. Neurodegenerative Disorders Market, 2018 - 2030 (USD Million)
5.7. Genetic Disorders
5.7.1. Genetic Disorders Market, 2018 - 2030 (USD Million)
5.8. Infectious Diseases
5.8.1. Infectious Diseases Market, 2018 - 2030 (USD Million)
5.9. Skin Diseases
5.9.1. Skin Diseases Market, 2018 - 2030 (USD Million)
5.10. Other
5.10.1. Other Market, 2018 - 2030 (USD Million)

Chapter 6. Route of Administration Business Analysis
6.1. Antisense and RNAi Therapeutics Market: Route of Administration Movement Analysis
6.2. Intravenous Injections
6.2.1. Intravenous Injections Market, 2018 - 2030 (USD Million)
6.3. Intrathecal Injections
6.3.1. Intrathecal Injections Market, 2018 - 2030 (USD Million)
6.4. Subcutaneous Injections
6.4.1. Subcutaneous Injections Market, 2018 - 2030 (USD Million)
6.5. Others
6.5.1. Others Market, 2018 - 2030 (USD Million)

Chapter 7. Regional Business Analysis
7.1. Antisense and RNAi Therapeutics Market Share By Region, 2022 & 2030
7.2. North America
7.2.1. North America Antisense and RNAi Therapeutics Market, 2018 - 2030 (USD Million)
7.2.2. U.S.
7.2.2.1. Key Country Dynamics
7.2.2.2. Target Disease Prevalence
7.2.2.3. Competitive Scenario
7.2.2.4. Regulatory Framework
7.2.2.5. U.S. Antisense and RNAi Therapeutics Market, 2018 - 2030 (USD Million)
7.2.3. Canada
7.2.3.1. Key Country Dynamics
7.2.3.2. Target Disease Prevalence
7.2.3.3. Competitive Scenario
7.2.3.4. Regulatory Framework
7.2.3.5. Canada Antisense and RNAi Therapeutics Market, 2018 - 2030 (USD Million)
7.3. Europe
7.3.1. Europe Antisense and RNAi Therapeutics Market, 2018 - 2030 (USD Million)
7.3.2. UK
7.3.2.1. Key Country Dynamics
7.3.2.2. Target Disease Prevalence
7.3.2.3. Competitive Scenario
7.3.2.4. Regulatory Framework
7.3.2.5. UK Antisense and RNAi Therapeutics Market, 2018 - 2030 (USD Million)
7.3.3. Germany
7.3.3.1. Key Country Dynamics
7.3.3.2. Target Disease Prevalence
7.3.3.3. Competitive Scenario
7.3.3.4. Regulatory Framework
7.3.3.5. Germany Antisense and RNAi Therapeutics Market, 2018 - 2030 (USD Million)
7.3.4. France
7.3.4.1. Key Country Dynamics
7.3.4.2. Target Disease Prevalence
7.3.4.3. Competitive Scenario
7.3.4.4. Regulatory Framework
7.3.4.5. France Antisense and RNAi Therapeutics Market, 2018 - 2030 (USD Million)
7.3.5. Italy
7.3.5.1. Key Country Dynamics
7.3.5.2. Target Disease Prevalence
7.3.5.3. Competitive Scenario
7.3.5.4. Regulatory Framework
7.3.5.5. Italy Antisense and RNAi Therapeutics Market, 2018 - 2030 (USD Million)
7.3.6. Spain
7.3.6.1. Key Country Dynamics
7.3.6.2. Target Disease Prevalence
7.3.6.3. Competitive Scenario
7.3.6.4. Regulatory Framework
7.3.6.5. Spain Antisense and RNAi Therapeutics Market, 2018 - 2030 (USD Million)
7.3.7. Denmark
7.3.7.1. Key Country Dynamics
7.3.7.2. Target Disease Prevalence
7.3.7.3. Competitive Scenario
7.3.7.4. Regulatory Framework
7.3.7.5. Denmark Antisense and RNAi Therapeutics Market, 2018 - 2030 (USD Million)
7.3.8. Sweden
7.3.8.1. Key Country Dynamics
7.3.8.2. Target Disease Prevalence
7.3.8.3. Competitive Scenario
7.3.8.4. Regulatory Framework
7.3.8.5. Sweden Antisense and RNAi Therapeutics Market, 2018 - 2030 (USD Million)
7.3.9. Norway
7.3.9.1. Key Country Dynamics
7.3.9.2. Target Disease Prevalence
7.3.9.3. Competitive Scenario
7.3.9.4. Regulatory Framework
7.3.9.5. Norway Antisense and RNAi Therapeutics Market, 2018 - 2030 (USD Million)
7.4. Asia Pacific
7.4.1. Asia Pacific Antisense and RNAi Therapeutics Market, 2018 - 2030 (USD Million)
7.4.2. Japan
7.4.2.1. Key Country Dynamics
7.4.2.2. Target Disease Prevalence
7.4.2.3. Competitive Scenario
7.4.2.4. Regulatory Framework
7.4.2.5. Japan Antisense and RNAi Therapeutics Market, 2018 - 2030 (USD Million)
7.4.3. China
7.4.3.1. Key Country Dynamics
7.4.3.2. Target Disease Prevalence
7.4.3.3. Competitive Scenario
7.4.3.4. Regulatory Framework
7.4.3.5. China Antisense and RNAi Therapeutics Market, 2018 - 2030 (USD Million)
7.4.4. India
7.4.4.1. Key Country Dynamics
7.4.4.2. Target Disease Prevalence
7.4.4.3. Competitive Scenario
7.4.4.4. Regulatory Framework
7.4.4.5. India Antisense and RNAi Therapeutics Market, 2018 - 2030 (USD Million)
7.4.5. Australia
7.4.5.1. Key Country Dynamics
7.4.5.2. Target Disease Prevalence
7.4.5.3. Competitive Scenario
7.4.5.4. Regulatory Framework
7.4.5.5. Australia Antisense and RNAi Therapeutics Market, 2018 - 2030 (USD Million)
7.4.6. Thailand
7.4.6.1. Key Country Dynamics
7.4.6.2. Target Disease Prevalence
7.4.6.3. Competitive Scenario
7.4.6.4. Regulatory Framework
7.4.6.5. Thailand Antisense and RNAi Therapeutics Market, 2018 - 2030 (USD Million)
7.4.7. South Korea
7.4.7.1. Key Country Dynamics
7.4.7.2. Target Disease Prevalence
7.4.7.3. Competitive Scenario
7.4.7.4. Regulatory Framework
7.4.7.5. South Korea Antisense and RNAi Therapeutics Market, 2018 - 2030 (USD Million)
7.5. Latin America
7.5.1. Latin America Antisense and RNAi Therapeutics Market, 2018 - 2030 (USD Million)
7.5.2. Brazil
7.5.2.1. Key Country Dynamics
7.5.2.2. Target Disease Prevalence
7.5.2.3. Competitive Scenario
7.5.2.4. Regulatory Framework
7.5.2.5. Brazil Antisense and RNAi Therapeutics Market, 2018 - 2030 (USD Million)
7.5.3. Mexico
7.5.3.1. Key Country Dynamics
7.5.3.2. Target Disease Prevalence
7.5.3.3. Competitive Scenario
7.5.3.4. Regulatory Framework
7.5.3.5. Mexico Antisense and RNAi Therapeutics Market, 2018 - 2030 (USD Million)
7.5.4. Argentina
7.5.4.1. Key Country Dynamics
7.5.4.2. Target Disease Prevalence
7.5.4.3. Competitive Scenario
7.5.4.4. Regulatory Framework
7.5.4.5. Argentina Antisense and RNAi Therapeutics Market, 2018 - 2030 (USD Million)
7.6. MEA
7.6.1. MEA Antisense and RNAi Therapeutics Market, 2018 - 2030 (USD Million)
7.6.2. South Africa
7.6.2.1. Key Country Dynamics
7.6.2.2. Target Disease Prevalence
7.6.2.3. Competitive Scenario
7.6.2.4. Regulatory Framework
7.6.2.5. South Africa Antisense and RNAi Therapeutics Market, 2018 - 2030 (USD Million)
7.6.3. Saudi Arabia
7.6.3.1. Key Country Dynamics
7.6.3.2. Target Disease Prevalence
7.6.3.3. Competitive Scenario
7.6.3.4. Regulatory Framework
7.6.3.5. Saudi Arabia Antisense and RNAi Therapeutics Market, 2018 - 2030 (USD Million)
7.6.4. UAE
7.6.4.1. Key Country Dynamics
7.6.4.2. Target Disease Prevalence
7.6.4.3. Competitive Scenario
7.6.4.4. Regulatory Framework
7.6.4.5. UAE Antisense and RNAi Therapeutics Market, 2018 - 2030 (USD Million)
7.6.5. Kuwait
7.6.5.1. Key Country Dynamics
7.6.5.2. Target Disease Prevalence
7.6.5.3. Competitive Scenario
7.6.5.4. Regulatory Framework
7.6.5.5. Kuwait Antisense and RNAi Therapeutics Market, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape
8.1. Company Categorization
8.2. Strategy Mapping
8.3. Company Market Share Analysis, 2022
8.4. Company Profiles/Listing
8.4.1. Olix Pharmaceuticals
8.4.1.1. Overview
8.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.1.3. Product Benchmarking
8.4.1.4. Strategic Initiatives
8.4.2. GSK plc.
8.4.2.1. Overview
8.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.2.3. Product Benchmarking
8.4.2.4. Strategic Initiatives
8.4.3. Sanofi Aventis / Genzyme
8.4.3.1. Overview
8.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.3.3. Product Benchmarking
8.4.3.4. Strategic Initiatives
8.4.4. Alnylam Pharmaceuticals
8.4.4.1. Overview
8.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.4.3. Product Benchmarking
8.4.4.4. Strategic Initiatives
8.4.5. Isis Pharmaceuticals/ Ionis Pharmaceuticals
8.4.5.1. Overview
8.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.5.3. Product Benchmarking
8.4.5.4. Strategic Initiatives
8.4.6. Benitec Biopharma Ltd.
8.4.6.1. Overview
8.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.6.3. Product Benchmarking
8.4.6.4. Strategic Initiatives
8.4.7. Arbutus Biopharma Ltd.
8.4.7.1. Overview
8.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.7.3. Product Benchmarking
8.4.7.4. Strategic Initiatives
8.4.8. Silence Therapeutics
8.4.8.1. Overview
8.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.8.3. Product Benchmarking
8.4.8.4. Strategic Initiatives
8.4.9. Bio-Path Holdings Inc.
8.4.9.1. Overview
8.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.9.3. Product Benchmarking
8.4.9.4. Strategic Initiatives
8.4.10. Antisense Therapeutics Limited.
8.4.10.1. Overview
8.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.10.3. Product Benchmarking
8.4.10.4. Strategic Initiatives

List of Tables
Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 Global Antisense and RNAi Therapeutics Market, By Technology, 2018 - 2030 (USD Million)
Table 4 Global Antisense and RNAi Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 5 Global Antisense and RNAi Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 6 Global Antisense and RNAi Therapeutics Market, By Region, 2018 - 2030 (USD Million)
Table 7 North America Antisense and RNAi Therapeutics Market, By Country, 2018 - 2030 (USD Million)
Table 8 North America Antisense and RNAi Therapeutics Market, By Technology, 2018 - 2030 (USD Million)
Table 9 North America Antisense and RNAi Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 10 North America Antisense and RNAi Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 11 U.S. Antisense and RNAi Therapeutics Market, By Technology, 2018 - 2030 (USD Million)
Table 12 U.S. Antisense and RNAi Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 13 U.S. Antisense and RNAi Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 14 Canada Antisense and RNAi Therapeutics Market, By Technology, 2018 - 2030 (USD Million)
Table 15 Canada Antisense and RNAi Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 16 Canada Antisense and RNAi Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 17 Europe Antisense and RNAi Therapeutics Market, By Country, 2018 - 2030 (USD Million)
Table 18 Europe Antisense and RNAi Therapeutics Market, By Technology, 2018 - 2030 (USD Million)
Table 19 Europe Antisense and RNAi Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 20 Europe Antisense and RNAi Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 21 UK Antisense and RNAi Therapeutics Market, By Technology, 2018 - 2030 (USD Million)
Table 22 UK Antisense and RNAi Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 23 UK Antisense and RNAi Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 24 Germany Antisense and RNAi Therapeutics Market, By Technology, 2018 - 2030 (USD Million)
Table 25 Germany Antisense and RNAi Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 26 Germany Antisense and RNAi Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 27 France Antisense and RNAi Therapeutics Market, By Technology, 2018 - 2030 (USD Million)
Table 28 France Antisense and RNAi Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 29 France Antisense and RNAi Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 30 Spain Antisense and RNAi Therapeutics Market, By Technology, 2018 - 2030 (USD Million)
Table 31 Spain Antisense and RNAi Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 32 Spain Antisense and RNAi Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 33 Italy Antisense and RNAi Therapeutics Market, By Technology, 2018 - 2030 (USD Million)
Table 34 Italy Antisense and RNAi Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 35 Italy Antisense and RNAi Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 36 Denmark Antisense and RNAi Therapeutics Market, By Technology, 2018 - 2030 (USD Million)
Table 37 Denmark Antisense and RNAi Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 38 Denmark Antisense and RNAi Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 39 Norway Antisense and RNAi Therapeutics Market, By Technology, 2018 - 2030 (USD Million)
Table 40 Norway Antisense and RNAi Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 41 Norway Antisense and RNAi Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 42 Sweden Antisense and RNAi Therapeutics Market, By Technology, 2018 - 2030 (USD Million)
Table 43 Sweden Antisense and RNAi Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 44 Sweden Antisense and RNAi Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 45 Asia Pacific Antisense and RNAi Therapeutics Market, By Country, 2018 - 2030 (USD Million)
Table 46 Asia Pacific Antisense and RNAi Therapeutics Market, By Technology, 2018 - 2030 (USD Million)
Table 47 Asia Pacific Antisense and RNAi Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 48 Asia Pacific Antisense and RNAi Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 49 China Antisense and RNAi Therapeutics Market, By Technology, 2018 - 2030 (USD Million)
Table 50 China Antisense and RNAi Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 51 China Antisense and RNAi Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 52 Japan Antisense and RNAi Therapeutics Market, By Technology, 2018 - 2030 (USD Million)
Table 53 Japan Antisense and RNAi Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 54 Japan Antisense and RNAi Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 55 India Antisense and RNAi Therapeutics Market, By Technology, 2018 - 2030 (USD Million)
Table 56 India Antisense and RNAi Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 57 India Antisense and RNAi Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 58 South Korea Antisense and RNAi Therapeutics Market, By Technology, 2018 - 2030 (USD Million)
Table 59 South Korea Antisense and RNAi Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 60 South Korea Antisense and RNAi Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 61 Australia Antisense and RNAi Therapeutics Market, By Technology, 2018 - 2030 (USD Million)
Table 62 Australia Antisense and RNAi Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 63 Australia Antisense and RNAi Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 64 Thailand Antisense and RNAi Therapeutics Market, By Technology, 2018 - 2030 (USD Million)
Table 65 Thailand Antisense and RNAi Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 66 Thailand Antisense and RNAi Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 67 Latin America Antisense and RNAi Therapeutics Market, By Country, 2018 - 2030 (USD Million)
Table 68 Latin America Antisense and RNAi Therapeutics Market, By Technology, 2018 - 2030 (USD Million)
Table 69 Latin America Antisense and RNAi Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 70 Latin America Antisense and RNAi Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 71 Brazil Antisense and RNAi Therapeutics Market, By Technology, 2018 - 2030 (USD Million)
Table 72 Brazil Antisense and RNAi Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 73 Brazil Antisense and RNAi Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 74 Mexico Antisense and RNAi Therapeutics Market, By Technology, 2018 - 2030 (USD Million)
Table 75 Mexico Antisense and RNAi Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 76 Mexico Antisense and RNAi Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 77 Argentina Antisense and RNAi Therapeutics Market, By Technology, 2018 - 2030 (USD Million)
Table 78 Argentina Antisense and RNAi Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 79 Argentina Antisense and RNAi Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 80 MEA Antisense and RNAi Therapeutics Market, By Country, 2018 - 2030 (USD Million)
Table 81 MEA Antisense and RNAi Therapeutics Market, By Technology, 2018 - 2030 (USD Million)
Table 82 MEA Antisense and RNAi Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 83 MEA Antisense and RNAi Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 84 South Africa Antisense and RNAi Therapeutics Market, By Technology, 2018 - 2030 (USD Million)
Table 85 South Africa Antisense and RNAi Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 86 South Africa Antisense and RNAi Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 87 UAE Antisense and RNAi Therapeutics Market, By Technology, 2018 - 2030 (USD Million)
Table 88 UAE Antisense and RNAi Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 89 UAE Antisense and RNAi Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 90 Saudi Arabia Antisense and RNAi Therapeutics Market, By Technology, 2018 - 2030 (USD Million)
Table 91 Saudi Arabia Antisense and RNAi Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 92 Saudi Arabia Antisense and RNAi Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 93 Kuwait Antisense and RNAi Therapeutics Market, By Technology, 2018 - 2030 (USD Million)
Table 94 Kuwait Antisense and RNAi Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 95 Kuwait Antisense and RNAi Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)

List of Figures
Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value chain-based sizing & forecasting
Fig. 6 Market formulation & validation
Fig. 7 Antisense and RNAi therapeutics market segmentation
Fig. 8 Market snapshot, 2022
Fig. 9 Market trends & outlook
Fig. 10 Market driver relevance analysis (current & future impact)
Fig. 11 Market restraint relevance analysis (current & future impact)
Fig. 12 PESTEL analysis
Fig. 13 Porter’s five forces analysis
Fig. 14 Global antisense and RNAi therapeutics market: Technology outlook and key takeaways
Fig. 15 Global antisense and RNAi therapeutics market: Technology movement analysis
Fig. 16 Global antisense and RNAi therapeutics market, for RNA interference, 2018 - 2030 (USD Million)
Fig. 17 Global antisense and RNAi therapeutics market, for siRNA, 2018 - 2030 (USD Million)
Fig. 18 Global antisense and RNAi therapeutics market, for miRNA, 2018 - 2030 (USD Million)
Fig. 19 Global antisense and RNAi therapeutics market, for Antisense RNA, 2018 - 2030 (USD Million)
Fig. 20 Global antisense and RNAi therapeutics market: Application outlook and key takeaways
Fig. 21 Global antisense and RNAi therapeutics market: Application movement analysis
Fig. 22 Global antisense and RNAi therapeutics market, for Ocular, 2018 - 2030 (USD Million)
Fig. 23 Global antisense and RNAi therapeutics market, for Cancer, 2018 - 2030 (USD Million)
Fig. 24 Global antisense and RNAi therapeutics market, for Cardio metabolic & Renal Disorders Diseases (CVDs), 2018 - 2030 (USD Million)
Fig. 25 Global antisense and RNAi therapeutics market, for Respiratory Disorders, 2018 - 2030 (USD Million)
Fig. 26 Global antisense and RNAi therapeutics market, for Skin Diseases, 2018 - 2030 (USD Million)
Fig. 27 Global antisense and RNAi therapeutics market, for Neurodegenerative Disorders, 2018 - 2030 (USD Million)
Fig. 28 Global antisense and RNAi therapeutics market, for Genetic Disorders, 2018 - 2030 (USD Million)
Fig. 29 Global antisense and RNAi therapeutics market, for Infectious Diseases, 2018 - 2030 (USD Million)
Fig. 30 Global antisense and RNAi therapeutics market, for Others, 2018 - 2030 (USD Million)
Fig. 31 Global antisense and RNAi therapeutics market: Route of Administration outlook and key takeaways
Fig. 32 Global antisense and RNAi therapeutics market: Route of Administration movement analysis
Fig. 33 Global antisense and RNAi therapeutics market, for Intravenous Injections, 2018 - 2030 (USD Million)
Fig. 34 Global antisense and RNAi therapeutics market, for Intrathecal Injections, 2018 - 2030 (USD Million)
Fig. 35 Global antisense and RNAi therapeutics market, for Subcutaneous Injections, 2018 - 2030 (USD Million)
Fig. 36 Global antisense and RNAi therapeutics market, for other delivery methods, 2018 - 2030 (USD Million)
Fig. 37 Regional marketplace: Key takeaways
Fig. 38 Regional outlook, 2022 & 2030
Fig. 39 Global antisense and RNAi therapeutics market: Region movement analysis
Fig. 40 North America antisense and RNAi therapeutics market, 2018 - 2030 (USD Million)
Fig. 41 U.S. antisense and RNAi therapeutics market, 2018 - 2030 (USD Million)
Fig. 42 Canada antisense and RNAi therapeutics market, 2018 - 2030 (USD Million)
Fig. 43 Europe antisense and RNAi therapeutics market, 2018 - 2030 (USD Million)
Fig. 44 Germany antisense and RNAi therapeutics market, 2018 - 2030 (USD Million)
Fig. 45 UK antisense and RNAi therapeutics market, 2018 - 2030 (USD Million)
Fig. 46 France antisense and RNAi therapeutics market, 2018 - 2030 (USD Million)
Fig. 47 Italy antisense and RNAi therapeutics market, 2018 - 2030 (USD Million)
Fig. 48 Spain antisense and RNAi therapeutics market, 2018 - 2030 (USD Million)
Fig. 49 Denmark antisense and RNAi therapeutics market, 2018 - 2030 (USD Million)
Fig. 50 Sweden antisense and RNAi therapeutics market, 2018 - 2030 (USD Million)
Fig. 51 Norway antisense and RNAi therapeutics market, 2018 - 2030 (USD Million)
Fig. 52 Asia Pacific antisense and RNAi therapeutics market, 2018 - 2030 (USD Million)
Fig. 53 Japan antisense and RNAi therapeutics market, 2018 - 2030 (USD Million)
Fig. 54 China antisense and RNAi therapeutics market, 2018 - 2030 (USD Million)
Fig. 55 India antisense and RNAi therapeutics market, 2018 - 2030 (USD Million)
Fig. 56 Australia antisense and RNAi therapeutics market, 2018 - 2030 (USD Million)
Fig. 57 South Korea antisense and RNAi therapeutics market, 2018 - 2030 (USD Million)
Fig. 58 Thailand antisense and RNAi therapeutics market, 2018 - 2030 (USD Million)
Fig. 59 Latin America antisense and RNAi therapeutics market, 2018 - 2030 (USD Million)
Fig. 60 Brazil antisense and RNAi therapeutics market, 2018 - 2030 (USD Million)
Fig. 61 Mexico antisense and RNAi therapeutics market, 2018 - 2030 (USD Million)
Fig. 62 Argentina antisense and RNAi therapeutics market, 2018 - 2030 (USD Million)
Fig. 63 Middle East and Africa antisense and RNAi therapeutics market, 2018 - 2030 (USD Million)
Fig. 64 South Africa antisense and RNAi therapeutics market, 2018 - 2030 (USD Million)
Fig. 65 Saudi Arabia antisense and RNAi therapeutics market, 2018 - 2030 (USD Million)
Fig. 66 UAE antisense and RNAi therapeutics market, 2018 - 2030 (USD Million)
Fig. 67 Kuwait antisense and RNAi therapeutics market, 2018 - 2030 (USD Million)